title: Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.
abstract: At diagnosis, approximately half of myelodysplastic (MDS) patients presents a normal karyotype by conventional cytogenetic analysis (CCA). Fluorescent in situ hybridization (FISH) is more sensitive than CCA allowing for the detection of minor clones and of submicroscopic lesions. We have analyzed by FISH 101 MDS patients with normal karyotype for the occurrence of the abnormalities which are most frequently observed in MDS (ie -5/5q-, -7/7q-, +8, 17p-). In 18 patients, 15 to 32% of interphase cells were found to carry one FISH abnormality. Six patients presented trisomy 8, five had del(5)(q31), five del(7)(q31), one monosomy 7 and one del(17)(p13). FISH abnormalities were more frequently observed among patients with an increased percentage of bone marrow blasts (P = 0.001). FISH abnormalities were also associated with a higher rate of progression into AML (13/18 vs 12/83, P < 0.001) and were predictive for a worse prognosis (P < 0.001). Multivariate analysis indicated that FISH positivity and IPSS risk group were independent predictors for a poor survival (P = 0.0057 and 0.0123, respectively) and for leukemic transformation (P = 0.0006 and 0.035, respectively). Leukemic transformation in FISH-positive patients was associated in all cases with an expansion of the abnormal clone. Our data demonstrated that a significant proportion of MDS patients with normal karyotype presented, if analyzed by FISH, clones of cytogenetically abnormal cells which played a determinant role in the progression of the disease. The presence of FISH abnormalities identified a group of MDS patients with normal karyotype characterized by an inferior prognosis.
authors.affiliation: Section of Hematology, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca, 203, 44100 Ferrara, Italy.
authors.forename: G M
authors.initials: GM
authors.lastname: Rigolin
authors.forename: R
authors.initials: R
authors.lastname: Bigoni
authors.forename: R
authors.initials: R
authors.lastname: Milani
authors.forename: F
authors.initials: F
authors.lastname: Cavazzini
authors.forename: M G
authors.initials: MG
authors.lastname: Roberti
authors.forename: A
authors.initials: A
authors.lastname: Bardi
authors.forename: P
authors.initials: P
authors.lastname: Agostini
authors.forename: M
authors.initials: M
authors.lastname: Della Porta
authors.forename: A
authors.initials: A
authors.lastname: Tieghi
authors.forename: N
authors.initials: N
authors.lastname: Piva
authors.forename: A
authors.initials: A
authors.lastname: Cuneo
authors.forename: G
authors.initials: G
authors.lastname: Castoldi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D002869:Chromosome Aberrations; D002999:Clone Cells / Q000473:pathology; D020732:Cytogenetic Analysis / Q000379:methods / Q000592:standards*; D018450:Disease Progression; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000592:standards; D007399:Interphase; D007621:Karyotyping; D008297:Male; D008677:Metaphase; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate